Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells

Bioconjugate Chemistry

Volumn 26, Issue 7, 2015, Pages 1307-1313

  Alshaer, Walhan ^a,b   Hillaireau, Hervé ^a   Vergnaud, Juliette ^a   Ismail, Said ^b   Fattal, Elias ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b THE UNIVERSITY OF JORDAN   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; CELL CULTURE; CELL MEMBRANES; DISEASES; DRUG DELIVERY; ELECTROPHORESIS; MEDICAL IMAGING; STEM CELLS; TUMORS;

APTAMERS; CANCER CELLS; CANCER STEM CELLS; CELL LINES; CELL SURFACE MARKER; HEAD AND NECK; MALEIMIDES; PEGYLATED LIPOSOMES; RECEPTORS PROTEINS; RNA APTAMER;

LIPOSOMES;

2' F PYRIMIDINE CONTAINING RNA APTAMER; ANTINEOPLASTIC AGENT; APTAMER; HYALURONIC ACID; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOSOME; MALEIMIDE; THIOL; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; HERMES ANTIGEN;

3T3 CELL LINE; AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING SITE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER RESISTANCE; CANCER SURVIVAL; CELL MIGRATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROSS LINKING; DRUG BINDING; DRUG CONJUGATION; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG UPTAKE; EMBRYO; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDRODYNAMICS; LIPOSOMAL DELIVERY; LUNG CANCER; LUNG CANCER CELL LINE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; SINGLE DRUG DOSE; STEREOSPECIFICITY; SURFACE PROPERTY; TARGET CELL; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; METABOLISM; NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD44; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MICE; NEOPLASMS; NIH 3T3 CELLS;

EID: 84937046469     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc5004313     Document Type: Article

References (37)

1. Dean, M., Fojo, T., and Bates, S. (2005) Tumour stem cells and drug resistance Nat. Rev. Cancer 5, 275-84
2. Visvader, J. E. (2011) Cells of origin in cancer Nature 469, 314-22
3. Vermeulen, L., de Sousa e Melo, F., Richel, D. J., and Medema, J. P. (2012) The developing cancer stem-cell model: clinical challenges and opportunities Lancet Oncol. 13, e83-9
4. Vermeulen, L., Sprick, M. R., Kemper, K., Stassi, G., and Medema, J. P. (2008) Cancer stem cells - old concepts, new insights Cell Death Differ. 15, 947-58
5. Clevers, H. (2011) The cancer stem cell: premises, promises and challenges Nat. Med. 17, 313-9
6. Magee, J. A., Piskounova, E., and Morrison, S. J. (2012) Cancer stem cells: impact, heterogeneity, and uncertainty Cancer Cell 21, 283-96
7. Schwarz-Cruz-y-Celis, A. and Melendez-Zajgla, J. (2011) Cancer stem cells Rev. Invest. Clin. 63, 179-86
8. Jones, R. J., Matsui, W. H., and Smith, B. D. (2004) Cancer stem cells: are we missing the target? J. Natl. Cancer Inst. 96, 583-5
9. Park, C. Y., Tseng, D., and Weissman, I. L. (2009) Cancer stem cell-directed therapies: recent data from the laboratory and clinic Mol. Ther. 17, 219-30
10. Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., and De Maria, R. (2007) Identification and expansion of human colon-cancer-initiating cells Nature 445, 111-5
11. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., and Clarke, M. F. (2003) Prospective identification of tumorigenic breast cancer cells Proc. Natl. Acad. Sci. U. S. A. 100, 3983-8
12. Eramo, A., Lotti, F., Sette, G., Pilozzi, E., Biffoni, M., Di Virgilio, A., Conticello, C., Ruco, L., Peschle, C., and De Maria, R. (2008) Identification and expansion of the tumorigenic lung cancer stem cell population Cell Death Differ. 15, 504-14
13. Hu, Y. and Fu, L. (2012) Targeting cancer stem cells: a new therapy to cure cancer patients Am. J. Cancer Res. 2, 340-56
14. Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., and Maitland, N. J. (2005) Prospective identification of tumorigenic prostate cancer stem cells Cancer Res. 65, 10946-51
15. Dalerba, P., Dylla, S. J., Park, I. K., Liu, R., Wang, X., Cho, R. W., Hoey, T., Gurney, A., Huang, E. H., Simeone, D. M., Shelton, A. A., Parmiani, G., Castelli, C., and Clarke, M. F. (2007) Phenotypic characterization of human colorectal cancer stem cells Proc. Natl. Acad. Sci. U. S. A. 104, 10158-63
16. Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., and Simeone, D. M. (2007) Identification of pancreatic cancer stem cells Cancer Res. 67, 1030-7
17. Zoller, M. (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat. Rev. Cancer 11, 254-67
18. Jayasena, S. D. (1999) Aptamers: an emerging class of molecules that rival antibodies in diagnostics Clin. Chem. 45, 1628-50
19. Tuerk, C. and Gold, L. (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249, 505-10
20. Ellington, A. D. and Szostak, J. W. (1990) In vitro selection of RNA molecules that bind specific ligands Nature 346, 818-22
21. Nimjee, S. M., Rusconi, C. P., and Sullenger, B. A. (2005) Aptamers: an emerging class of therapeutics Annu. Rev. Med. 56, 555-83
22. Keefe, A. D., Pai, S., and Ellington, A. (2010) Aptamers as therapeutics Nat. Rev. Drug Discovery 9, 537-50
23. Foy, J. W., Rittenhouse, K., Modi, M., and Patel, M. (2007) Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit J. Ocul. Pharmacol. Ther. 23, 452-66
24. Noble, G. T., Stefanick, J. F., Ashley, J. D., Kiziltepe, T., and Bilgicer, B. (2014) Ligand-targeted liposome design: challenges and fundamental considerations Trends Biotechnol. 32, 32-45
25. Allen, T. M. and Cullis, P. R. (2013) Liposomal drug delivery systems: from concept to clinical applications Adv. Drug Delivery Rev. 65, 36-48
26. Eliaz, R. and Szoka, F. (2001) Liposome-encapsulated doxorubicin targeted to CD44: A strategy to kill CD44-overexpressing tumor cells Cancer Res. 61, 2592-2601
27. Verel, I., Heider, K. H., Siegmund, M., Ostermann, E., Patzelt, E., Sproll, M., Snow, G. B., Adolf, G. R., and van Dongen, G. A. (2002) Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts Int. J. Cancer 99, 396-402
28. Derksen, J. T., Morselt, H. W., and Scherphof, G. L. (1988) Uptake and processing of immunoglobulin-coated liposomes by subpopulations of rat liver macrophages Biochim. Biophys. Acta 971, 127-136
29. Harding, J. A., Engbers, C. M., Newman, M. S., Goldstein, N. I., and Zalipsky, S. (1997) Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes Biochim. Biophys. Acta 1327, 181-192
30. Powell, J. D. and Horton, M. R. (2005) Threat matrix: lowmolecular-weight hyaluronan (HA) as a danger signal Immunol. Res. 31, 207-218
31. Ababneh, N., Alshaer, W., Allozi, O., Mahafzah, A., El-Khateeb, M., Hillaireau, H., Noiray, M., Fattal, E., and Ismail, S. (2013) In vitro selection of modified RNA aptamers against CD44 cancer stem cell marker Nucleic Acid Ther. 23, 401-7
32. Levy-Nissenbaum, E., Radovic-Moreno, A. F., Wang, A. Z., Langer, R., and Farokhzad, O. C. (2008) Nanotechnology and aptamers: applications in drug delivery Trends Biotechnol. 26, 442-9
33. Bangham, A. D., Standish, M. M., Watkins, J. C., and Weissmann, G. (1967) The diffusion of ions from a phospholipid model membrane system Protoplasma 63, 183-7
34. Da Pieve, C., Williams, P., Haddleton, D. M., Palmer, R. M., and Missailidis, S. (2010) Modification of thiol functionalized aptamers by conjugation of synthetic polymers Bioconjugate Chem. 21, 169-74
35. Korkaya, H., Liu, S., and Wicha, M. (2011) Regulation of cancer stem cells by cytokine networks: attacking cancers inflammatory roots Clin. Cancer Res. 17, 6125-9
36. Yasuda, M., Tanaka, Y., Fujii, K., and Yasumoto, K. (2001) CD44 stimulation down-regulates Fas expression and Fas-mediated apoptosis of lung cancer cells Int. Immunol. 13, 1309-1319
37. Collins, S. L., Black, K. E., Chan-Li, Y., Ahn, Y., Cole, P. A., Powell, J. D., and Horton, M. R. (2011) Hyaluronan fragments promote inflammation by down-regulating the anti- inflammatory A2A receptor Am. J. Respir. Cell Mol. Biol. 45, 675-683